EU Biosimilar Regulatory and Launch Updates
Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar
FDA Approves Ustekinumab, Aflibercept, and Filgrastim Biosimilars
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab
Alexion Sues Samsung over Proposed Eculizumab Biosimilar
FDA Approves LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Scheduling Order Issued in REGENXBIO v. Sarepta Litigation
Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent
FDA Accepts BLA for Dr. Reddy’s Rituximab Biosimilar for Review
Subscribe: Subscribe via RSS
Blogs
Firm/Org